{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:15:07Z","timestamp":1791206107666,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12253-013-9677-2","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T02:18:41Z","timestamp":1377051521000},"page":"145-151","source":"Crossref","is-referenced-by-count":65,"title":["BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma"],"prefix":"10.1007","volume":"20","author":[{"given":"Lisa","family":"Arzt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Halbwedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut H.","family":"Popper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"issue":"2","key":"9677_CR1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1874467210902020190","volume":"2","author":"M Tomasetti","year":"2009","unstructured":"Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J (2009) Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2(2):190\u2013206","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"9677_CR2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/172460080902400208","volume":"24","author":"L Paleari","year":"2009","unstructured":"Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M (2009) Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 24(2):112\u2013117","journal-title":"Int J Biol Markers"},{"issue":"3","key":"9677_CR3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/14728210903074563","volume":"14","author":"C Belli","year":"2009","unstructured":"Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L (2009) Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 14(3):423\u2013437. doi: 10.1517\/14728210903074563","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"9677_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejcts.2005.10.008","volume":"29","author":"S Neragi-Miandoab","year":"2006","unstructured":"Neragi-Miandoab S (2006) Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(1):14\u201319. doi: 10.1016\/j.ejcts.2005.10.008","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9440","key":"9677_CR5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(04)17108-0","volume":"364","author":"T Treasure","year":"2004","unstructured":"Treasure T, Sedrakyan A (2004) Pleural mesothelioma: little evidence, still time to do trials. Lancet 364(9440):1183\u20131185. doi: 10.1016\/s0140-6736(04)17108-0","journal-title":"Lancet"},{"key":"9677_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-3-34","volume":"3","author":"AJ Moore","year":"2008","unstructured":"Moore AJ, Parker RJ, Wiggins J (2008) Malignant mesothelioma. Orphanet J Rare Dis 3:34. doi: 10.1186\/1750-1172-3-34","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"9677_CR7","first-page":"13","volume":"105","author":"C Montjoy","year":"2009","unstructured":"Montjoy C, Parker J, Petsonk L, Luis T, Fallon K (2009) Mesothelioma review. W V Med J 105(3):13\u201316","journal-title":"W V Med J"},{"issue":"6","key":"9677_CR8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/carcin\/23.6.1017","volume":"23","author":"GJ Gordon","year":"2002","unstructured":"Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R (2002) Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23(6):1017\u20131024","journal-title":"Carcinogenesis"},{"issue":"24","key":"9677_CR9","doi-asserted-by":"crossref","first-page":"14133","DOI":"10.1073\/pnas.2232790100","volume":"100","author":"B He","year":"2003","unstructured":"He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 100(24):14133\u201314138. doi: 10.1073\/pnas.2232790100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"9677_CR10","first-page":"687","volume":"1","author":"C Xia","year":"2002","unstructured":"Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1(9):687\u2013694","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"9677_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0169-5002(01)00257-4","volume":"34","author":"GL Ceresoli","year":"2001","unstructured":"Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E (2001) Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34(2):279\u2013287","journal-title":"Lung Cancer"},{"issue":"10","key":"9677_CR12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","volume":"2","author":"RM Flores","year":"2007","unstructured":"Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2(10):957\u2013965. doi: 10.1097\/JTO.0b013e31815608d9","journal-title":"J Thorac Oncol"},{"issue":"4","key":"9677_CR13","first-page":"210","volume":"65","author":"L Proietti","year":"2006","unstructured":"Proietti L, Spicuzza L, Di Maria A, Polosa R, Sebastian Torres E, Asero V, Di Maria GU (2006) Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres. Monaldi Arch Chest Dis 65(4):210\u2013216","journal-title":"Monaldi Arch Chest Dis"},{"issue":"10","key":"9677_CR14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022\u20131025. doi: 10.1038\/ng.912","journal-title":"Nat Genet"},{"issue":"9","key":"9677_CR15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","volume":"16","author":"DE Jensen","year":"1998","unstructured":"Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ 3rd (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16(9):1097\u20131112","journal-title":"Oncogene"},{"key":"9677_CR16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1749-6632.1999.tb09414.x","volume":"886","author":"DE Jensen","year":"1999","unstructured":"Jensen DE, Rauscher FJ 3rd (1999) BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci 886:191\u2013194","journal-title":"Ann N Y Acad Sci"},{"issue":"17","key":"9677_CR17","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","volume":"68","author":"KH Ventii","year":"2008","unstructured":"Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD (2008) BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 68(17):6953\u20136962. doi: 10.1158\/0008-5472.can-08-0365","journal-title":"Cancer Res"},{"issue":"6009","key":"9677_CR18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410\u20131413. doi: 10.1126\/science.1194472","journal-title":"Science"},{"issue":"10","key":"9677_CR19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018\u20131021. doi: 10.1038\/ng.910","journal-title":"Nat Genet"},{"issue":"12","key":"9677_CR20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","volume":"48","author":"MH Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856\u2013859. doi: 10.1136\/jmedgenet-2011-100156","journal-title":"J Med Genet"},{"issue":"1","key":"9677_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","volume":"10","author":"M Carbone","year":"2012","unstructured":"Carbone M, Korb Ferris L, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, Yang H (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10(1):179. doi: 10.1186\/1479-5876-10-179","journal-title":"J Transl Med"},{"key":"9677_CR22","author":"T Wiesner","year":"2012","unstructured":"Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Juttner F, Geigl JB, Speicher MR (2012) Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol. doi: 10.1200\/jco.2011.41.2965","journal-title":"J Clin Oncol"},{"issue":"3","key":"9677_CR23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","volume":"135","author":"RM Flores","year":"2008","unstructured":"Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW (2008) Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620\u2013626. doi: 10.1016\/j.jtcvs.2007.10.054 , 626 e621-623","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"9677_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.semtcvs.2009.06.008","volume":"21","author":"RM Flores","year":"2009","unstructured":"Flores RM (2009) Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy\/decortication. Semin Thorac Cardiovasc Surg 21(2):149\u2013153. doi: 10.1053\/j.semtcvs.2009.06.008","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"7","key":"9677_CR25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43(7):668\u2013672. doi: 10.1038\/ng.855","journal-title":"Nat Genet"},{"key":"9677_CR26","author":"M Ladanyi","year":"2012","unstructured":"Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti FG (2012) New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. doi: 10.1158\/1078-0432.ccr-11-2375","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9677_CR27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","volume":"103","author":"Y Yoshikawa","year":"2012","unstructured":"Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Nakano T, Hashimoto-Tamaoki T (2012) Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 103(5):868\u2013874. doi: 10.1111\/j.1349-7006.2012.02223.x","journal-title":"Cancer Sci"},{"issue":"12","key":"9677_CR28","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/ncb1659","volume":"9","author":"R Kittler","year":"2007","unstructured":"Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M, Miroslaw L, Poser I, Lawo S, Grabner H, Kozak K, Wagner J, Surendranath V, Richter C, Bowen W, Jackson AL, Habermann B, Hyman AA, Buchholz F (2007) Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 9(12):1401\u20131412. doi: 10.1038\/ncb1659","journal-title":"Nat Cell Biol"},{"issue":"24","key":"9677_CR29","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.1093\/emboj\/cdf691","volume":"21","author":"DL Mallery","year":"2002","unstructured":"Mallery DL, Vandenberg CJ, Hiom K (2002) Activation of the E3 ligase function of the BRCA1\/BARD1 complex by polyubiquitin chains. EMBO J 21(24):6755\u20136762","journal-title":"EMBO J"},{"issue":"5863","key":"9677_CR30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1126\/science.1149200","volume":"319","author":"MR Schlabach","year":"2008","unstructured":"Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ (2008) Cancer proliferation gene discovery through functional genomics. Science 319(5863):620\u2013624. doi: 10.1126\/science.1149200","journal-title":"Science"},{"issue":"6","key":"9677_CR31","first-page":"2108","volume":"9","author":"PB Illei","year":"2003","unstructured":"Illei PB, Rusch VW, Zakowski MF, Ladanyi M (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9(6):2108\u20132113","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9677_CR32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","volume":"453","author":"S Dacic","year":"2008","unstructured":"Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H (2008) Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 453(6):627\u2013635. doi: 10.1007\/s00428-008-0689-3","journal-title":"Virchows Arch"},{"issue":"2","key":"9677_CR33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","volume":"64","author":"C Thurneysen","year":"2009","unstructured":"Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E (2009) Functional inactivation of NF2\/merlin in human mesothelioma. Lung Cancer 64(2):140\u2013147. doi: 10.1016\/j.lungcan.2008.08.014","journal-title":"Lung Cancer"},{"issue":"49","key":"9677_CR34","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","volume":"284","author":"YJ Machida","year":"2009","unstructured":"Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A (2009) The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 284(49):34179\u201334188. doi: 10.1074\/jbc.M109.046755","journal-title":"J Biol Chem"},{"issue":"8","key":"9677_CR35","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","volume":"29","author":"S Misaghi","year":"2009","unstructured":"Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, Liu J, O\u2019Rourke K, Dixit VM, Wilson AC (2009) Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 29(8):2181\u20132192. doi: 10.1128\/mcb.01517-08","journal-title":"Mol Cell Biol"},{"issue":"2","key":"9677_CR36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cell.2009.04.042","volume":"138","author":"ME Sowa","year":"2009","unstructured":"Sowa ME, Bennett EJ, Gygi SP, Harper JW (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138(2):389\u2013403. doi: 10.1016\/j.cell.2009.04.042","journal-title":"Cell"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-013-9677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-013-9677-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-013-9677-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T14:28:58Z","timestamp":1563719338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-013-9677-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["9677"],"URL":"https:\/\/doi.org\/10.1007\/s12253-013-9677-2","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]}}}